New filler trial aims to restore youthful cheeks
NCT ID NCT07126912
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a hyaluronic acid filler called Alcarisa for people with moderate to significant mid-face volume loss. Thirty participants aged 30 to 65 will receive a single injection in the cheek area and be followed for 24 weeks. Doctors will assess results using photos and a volume deficit scale, and participants will report their satisfaction.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Alcarisa hyaluronic acid filler
- What this could lead to
- If it works, this could provide a safe, effective option for restoring mid-face volume with a single injection.
- What could go wrong
- This is a small, early-stage study with only 30 participants and no comparison group. Results may not apply to everyone, and risks include allergic reactions or unsatisfactory results.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MID FACE VOLUME DEFICIT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Research and Training in Skin Disease and Leprocy
RECRUITINGTehran, Tehran Province, 1416613675, Iran
-
Orchid Pharmed, Medical Department
RECRUITINGTehran, Tehran Province, 19947-66411, Iran
More trials for these conditions
Other studies related to the condition(s) this trial covers.